{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diseases+of+Liver",
    "query": {
      "condition": "Diseases of Liver"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 4248,
    "total_pages": 425,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Diseases+of+Liver&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-23T03:42:46.294Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05792423",
      "title": "Conditionally Increased Output (CIO) Enhanced Ultrasound System",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Nonalcoholic Fatty Liver",
        "Nonalcoholic Steatohepatitis",
        "Fatty Liver"
      ],
      "interventions": [
        {
          "name": "GE ultrasound system with increased acoustic output settings",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2023-06-30",
      "completion_date": "2024-05-31",
      "has_results": true,
      "last_update_posted_date": "2025-05-23",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05792423"
    },
    {
      "nct_id": "NCT00091182",
      "title": "Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Childhood Central Nervous System Germ Cell Tumor",
        "Childhood Extragonadal Germ Cell Tumor",
        "Childhood Hepatoblastoma",
        "Childhood Hepatocellular Carcinoma",
        "Childhood High-grade Cerebral Astrocytoma",
        "Childhood Low-grade Cerebral Astrocytoma",
        "Childhood Malignant Ovarian Germ Cell Tumor",
        "Childhood Malignant Testicular Germ Cell Tumor",
        "Childhood Teratoma",
        "Recurrent Adrenocortical Carcinoma",
        "Recurrent Childhood Brain Stem Glioma",
        "Recurrent Childhood Cerebellar Astrocytoma",
        "Recurrent Childhood Cerebral Astrocytoma",
        "Recurrent Childhood Ependymoma",
        "Recurrent Childhood Liver Cancer",
        "Recurrent Childhood Malignant Germ Cell Tumor",
        "Recurrent Childhood Rhabdomyosarcoma",
        "Recurrent Childhood Soft Tissue Sarcoma",
        "Recurrent Childhood Visual Pathway and Hypothalamic Glioma",
        "Recurrent Colon Cancer",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Nasopharyngeal Cancer",
        "Recurrent Neuroblastoma",
        "Recurrent Osteosarcoma",
        "Recurrent Rectal Cancer",
        "Recurrent Renal Cell Cancer"
      ],
      "interventions": [
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 180,
      "start_date": "2004-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 1,
      "location_summary": "Arcadia, California",
      "locations": [
        {
          "city": "Arcadia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00091182"
    },
    {
      "nct_id": "NCT03245580",
      "title": "Benign Liver Optimal Core Study (Tissue Acquisition Comparison in Benign Liver Disease)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Liver Diseases"
      ],
      "interventions": [
        {
          "name": "Core Liver Biopsy",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Parkview Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 153,
      "start_date": "2018-03-08",
      "completion_date": "2020-09-15",
      "has_results": true,
      "last_update_posted_date": "2022-04-07",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 7,
      "location_summary": "Mobile, Alabama • San Jose, California • Fort Wayne, Indiana + 4 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "San Jose",
          "state": "California"
        },
        {
          "city": "Fort Wayne",
          "state": "Indiana"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03245580"
    },
    {
      "nct_id": "NCT02420496",
      "title": "Enteral Fish Oil is Superior to Ursodeoxycholic Acid (UDCA) and Placebo for the Treatment of Cholestasis in Infants",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cholestasis",
        "Liver Disease"
      ],
      "interventions": [
        {
          "name": "Enteral fish oil",
          "type": "DRUG"
        },
        {
          "name": "Ursodeoxycholic Acid",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Days",
        "maximum_age": "24 Months",
        "sex": "ALL",
        "summary": "14 Days to 24 Months"
      },
      "enrollment_count": 0,
      "start_date": "2016-06",
      "completion_date": "2016-06",
      "has_results": false,
      "last_update_posted_date": "2016-06-21",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 1,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02420496"
    },
    {
      "nct_id": "NCT00039962",
      "title": "Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C",
        "Hepatitis C, Chronic"
      ],
      "interventions": [
        {
          "name": "thymalfasin (thymosin alpha 1)",
          "type": "DRUG"
        },
        {
          "name": "PEGinterferon alfa-2a",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "SciClone Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 500,
      "start_date": "2002-05",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-01-15",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 54,
      "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Anaheim, California + 43 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00039962"
    },
    {
      "nct_id": "NCT04812262",
      "title": "A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Overweight and Obesity",
        "Type2 Diabetes",
        "NAFLD"
      ],
      "interventions": [
        {
          "name": "DD01",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Neuraly, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 255,
      "start_date": "2021-02-24",
      "completion_date": "2023-02-14",
      "has_results": false,
      "last_update_posted_date": "2024-04-29",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 3,
      "location_summary": "Chula Vista, California • Fort Myers, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Chula Vista",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04812262"
    },
    {
      "nct_id": "NCT01425970",
      "title": "Chronically-infected HCV Genotype 2 and 3 Treatment-naive Subjects: Part A: Safety and Efficacy of INX-08189 With Peg IFN Alfa-2a and Ribavirin. Part B: INX-08189 in Interferon Free Treatment With Daclatasvir and/or Ribavirin",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "INX-08189",
          "type": "DRUG"
        },
        {
          "name": "Placebo matching with INX-08189",
          "type": "DRUG"
        },
        {
          "name": "Pegylated interferon alfa-2a",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Daclatasvir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 210,
      "start_date": "2012-05",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2015-11-04",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • La Jolla, California • San Francisco, California + 3 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Tulsa",
          "state": "Oklahoma"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01425970"
    },
    {
      "nct_id": "NCT01464827",
      "title": "ABT-450 With Ritonavir and ABT-267 and/or ABT-333 With and Without Ribavirin in Genotype 1 Hepatitis C Virus Infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Hepatitis C",
        "Hepatitis C (HCV)",
        "Hepatitis C Genotype 1"
      ],
      "interventions": [
        {
          "name": "ABT-450",
          "type": "DRUG"
        },
        {
          "name": "ABT-333",
          "type": "DRUG"
        },
        {
          "name": "ABT-267",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Ritonavir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 580,
      "start_date": "2011-10",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-04-22",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 60,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 52 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01464827"
    },
    {
      "nct_id": "NCT00319683",
      "title": "A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Hepatocellular Carcinoma"
      ],
      "interventions": [
        {
          "name": "ADH300004",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Adherex Technologies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2008-12-15",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 1,
      "location_summary": "Honolulu, Hawaii",
      "locations": [
        {
          "city": "Honolulu",
          "state": "Hawaii"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00319683"
    },
    {
      "nct_id": "NCT01371396",
      "title": "Effect of Dietary Macronutrient Composition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Metabolic Syndrome",
        "Non-alcoholic Fatty Liver Disease",
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Low-fat diet",
          "type": "OTHER"
        },
        {
          "name": "Low-carbohydrate diet",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "20 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2007-09-01",
      "completion_date": "2013-12-31",
      "has_results": false,
      "last_update_posted_date": "2019-02-06",
      "last_synced_at": "2026-09-23T03:42:46.294Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01371396"
    }
  ]
}